CD8A and melanoma: Earlier attempts at releasing the suppression of conventional CD4+ and CD8+ T cells in CRC with anti-PD-1 and anti-CTLA-4 blockade, which have shown excellent results in therapy of advanced melanoma and prostate cancer, have failed, and so far no specific immunotherapy has been registered for CRC [51].